PropertyValue
?:abstract
  • An increasing number of people is affected by fungal biofilm-based infections, which are resistant to the majority of currently-used antifungal drugs. Such infections are often caused by species from the genera Candida, Aspergillus or Cryptococcus. Only a few antifungal drugs, including echinocandins and liposomal formulations of amphotericin B, are available to treat such biofilm-based fungal infections. This review discusses combination therapy as a novel antibiofilm strategy. More specifically, in vitro methods to discover new antibiofilm combinations will be discussed. Furthermore, an overview of the main modes of action of promising antibiofilm combination treatments will be provided as this knowledge may facilitate the optimization of existing antibiofilm combinations or the development of new ones with a similar mode of action.
is ?:annotates of
?:creator
?:doi
  • 10.3390/ijms21228873
?:doi
?:journal
  • Int_J_Mol_Sci
?:license
  • cc-by
?:pdf_json_files
  • document_parses/pdf_json/c6dda05d8666f9aa88a49194ce2ded9e624682fe.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7700406.xml.json
?:pmcid
?:pmid
?:pmid
  • 33238622.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:sha_id
?:source
  • Medline; PMC
?:title
  • Combination Therapy to Treat Fungal Biofilm-Based Infections
?:type
?:year
  • 2020-11-23

Metadata

Anon_0  
expand all